查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1933293

全球奈米医学市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考察、未来预测（2026-2034）

Nanomedicine Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 200 Pages | 商品交期: 请询问到货日

价格

奈米医学市场成长因素

2025年，全球奈米医学（奈米药物）市场规模为2,636.8亿美元。预计该市场将从2026年的2,890.2亿美元成长到2034年的7,590.9亿美元，在预测期（2026-2034年）内年复合成长率（CAGR）为12.83%。

北美地区在全球奈米医学市场占据主导地位，到2025年占据46.12%的市场占有率，这主要得益于其先进的医疗基础设施、强大的研发能力以及慢性病的高发生率。

奈米医学是将奈米技术应用于医学诊断、药物传输和治疗介入，利用尺寸介于 1 至 100 奈米之间的奈米级材料。这些技术能够实现标靶递送、提高生物利用度并降低全身毒性，使其在治疗复杂的慢性疾病方面非常有效。奈米颗粒在製药、诊断、生物医学植入物、组织工程和再生医学领域的日益广泛应用，推动全球市场的成长。

市场概览

受精准医疗和先进治疗方案需求不断成长的驱动，全球奈米医学市场正经历强劲成长。基于奈米技术的平台正用来提高药物的溶解度、稳定性和缓释性，进而改善患者的治疗效果。奈米技术研究投入的增加、临床试验的增加以及奈米药物和医疗器材获批数量的成长，进一步巩固了市场格局。

癌症、心血管疾病、神经退化性疾病和糖尿病等慢性疾病的日益增多，显着提升了对标靶、微创治疗的需求，使奈米医学成为现代医学的关键组成部分。

市场动态

市场驱动因素

慢性疾病盛行率上升

全球慢性疾病发生率的不断上升是推动奈米医学市场成长的主要因素。癌症、糖尿病、心血管疾病、神经退化性疾病和免疫相关疾病等病症需要长期、标靶的治疗方法。

传统疗法常面临疗效低、脱靶毒性和生物利用度有限等挑战。奈米医学透过实现可控的、标靶的药物递送，有效应对这些挑战，在提高疗效的同时，最大限度地减少副作用。

例如，根据美国肺臟协会的资料，美国肺癌病例从2019年的221,097例增加到2023年的238,000例。这种日益加重的疾病负担推动对基于奈米技术的诊断和标靶癌症治疗的需求，支撑市场成长。

对标靶药物递送系统的需求不断成长

人们越来越关注传统药物递送方法的副作用，这推动了对标靶药物递送系统的需求。脂质体、脂质奈米颗粒、聚合物-药物偶联物和无机奈米颗粒等奈米载体能够将药物直接递送到病变细胞，提高疗效并降低全身毒性。

製药和生物技术公司持续进行研发活动并推出先进的奈米递送系统产品，这大幅促进了市场扩张。

市场限制因子

高成本与监理挑战

由于需要专用设备、先进的製造流程和专业技术，奈米药物的开发和商业化成本高昂。这些高成本可能会限制中小企业进入该领域。

此外，严格的监管要求，特别是安全性和毒性评估方面的要求，以及复杂的审批流程，都对市场成长构成挑战。缺乏标准化的全球监管框架进一步加剧了审批流程的复杂性，导致产品上市延迟。

市场机会

奈米机器人在药物传递与诊断的应用

奈米机器人技术在医疗领域的应用蕴藏着巨大的成长机会。奈米机器人能够实现超精准的药物递送，并在细胞和分子层面上进行即时诊断。对基于奈米机器人技术的医疗解决方案的投资不断增加，尤其是在新兴市场，预计将为市场参与者创造获利机会。

例如，2024年11月，印度公司Theranautilus筹集了120万美元的种子资金，用于开发基于纳米机器人技术的医疗器械，这凸显了投资者对该领域日益成长的兴趣。

市场挑战

缺乏标准化的监管架构

奈米医学市场面临的主要挑战之一是缺乏跨地区的标准化监管指南。这导致生产、品质控制和商业化方面存在不确定性。此外，临床试验的高昂成本和漫长的研发週期也构成障碍，尤其对中小企业而言更是如此。监管机构、研究人员和利害关係人之间需要通力合作，以简化审批流程，同时确保病人安全。

最新趋势

加速向个人化医疗转型

个人化医疗和精准医疗正成为全球奈米医学市场的主要趋势。奈米技术能够根据患者的基因、分子和表型特征量身定制治疗方案，改善疗效并减少副作用。

生物製药公司加速开发基于奈米技术的抗体药物偶联物（ADC）、生物标记靶向奈米颗粒和个人化药物递送平台。预计这些进展将在整个预测期内推动市场成长。

细分市场分析

依类型划分

市场依类型分为治疗药物、诊断试剂和医疗器材。

受奈米药物递送系统在慢性病和遗传疾病治疗领域日益普及的推动，治疗领域将在2026年占据市场主导地位，市场占有率将达到55.95%。

诊断领域将占据第二大市场占有率，这主要得益于对早期精准疾病诊断需求的不断成长。

医疗器材领域预计将显着成长，这主要得益于再生医学和奈米涂层植入物的进步。

依颗粒类型划分

市场依颗粒类型分为奈米颗粒、奈米壳、奈米管和奈米装置。

预计到2026年，奈米颗粒领域将占据最大的市场占有率，达到76.20%，这主要得益于其在药物递送和诊断领域的广泛应用。脂质和聚合物基奈米颗粒因其良好的生物相容性和稳定性而广泛采用。由于奈米壳在标靶癌症治疗领域的应用不断扩展，预计其市场将呈现强劲成长。

依应用领域划分

市场依应用领域细分为肿瘤学、神经退化性疾病、心血管疾病、免疫系统疾病、传染病及其他领域。

预计到2026年，肿瘤学领域将占据市场主导地位，市场占有率达43.52%，这主要得益于癌症患者数量的增加和新产品的持续推出。由于基于奈米技术的脑部标靶疗法的进步，神经退化性疾病领域预计将以显着的年复合成长率成长。

依最终使用者划分

市场依最终用户细分为医院和诊所、诊断实验室、研究和学术机构及其他机构。

预计到2026年，医院和诊所将以49.86%的市场占有率引领市场，这主要得益于患者数量的成长和标靶疗法的日益普及。由于对奈米医学研发的日益重视，研究机构和学术机构预计将实现最高的成长率。

区域展望

到2025年，北美地区的市场收入达到1,216.1亿美元，主要得益于FDA核准数量的增加和强劲的研发投入。

预计亚太地区将以最高的年复合成长率成长，这主要得益于临床试验的增加、政府资金的投入以及中国、日本和印度医疗基础设施的不断完善。

欧洲凭藉其先进的医疗体系和强大的研究合作，占据了较大的市场占有率。

预计拉丁美洲以及中东和非洲地区将保持稳定成长，这主要得益于研究网路的完善和医疗投资的增加。

这些公司致力于策略合作、收购、研发投资和产品发布，以巩固其市场地位。

产业主要动态

  • 2023年9月：Evonik扩大其用于肠外给药的奈米颗粒技术组合。
  • 2023年6月：BIONANOSIM与RAFARM合作成立BNS Ophthalmics。
  • 2023年3月：Moderna与Generation Bio合作开发非病毒基因治疗药物。
  • 2022年1月：Pfizer与Aquitas Therapeutics就脂质奈米颗粒递送系统达成开发协议。

随着癌症、心血管疾病、神经退化性疾病和传染病等慢性疾病负担的持续加重，对基于奈米技术的诊断和治疗的需求也在不断成长。治疗药物类别和奈米颗粒分子类型的主导地位表明，人们越来越依赖奈米平台来提高药物疗效、安全性和患者预后。此外，由于标靶癌症疗法的持续创新和产品上市，肿瘤领域仍是主要的收入来源。

依地区划分，北美凭藉强有力的监管支持、高额的研发投入和大量已获批准的奈米药物，保持着领先地位。同时，由于临床试验的增加、政府资助和不断扩大的医疗基础设施，亚太地区预计将实现最快的成长。欧洲则继续受益于强大的研究合作和先进的医疗保健系统。

儘管面临高昂的研发成本和复杂的监管等挑战，但持续的技术创新、不断增加的投资以及对奈米机器人和个人化医疗日益成长的关注预计将增强市场前景。主要公司的策略性举措，包括合作、收购和新产品开发，可能会在预测期内进一步加速奈米药物在多个治疗领域的应用。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 主要考察

  • 主要国家和地区主要疾病盛行率（2025年）
  • 概述：奈米医学在医疗领域的应用
  • 主要产业趋势（併购、合作、新产品发表等）
  • 研发管线分析
  • 新冠疫情对全球奈米医学的影响市场

第5章 全球奈米医学市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依类型划分
    • 治疗药物
      • 生物药物
      • 小分子
    • 诊断药
      • 体外诊断
      • 成像
      • 其他
    • 医疗器材
      • 再生医学
      • 植入物
  • 市场分析、洞察与预测：颗粒类型
    • 奈米颗粒
      • 脂质奈米颗粒
      • 聚合物及聚合物-药物偶联物
      • 无机奈米颗粒
      • 其他
    • 奈米壳
    • 奈米管
    • 奈米装置
  • 市场分析、洞察与预测：依应用领域划分
    • 肿瘤学
    • 神经退化性疾病
    • 心血管疾病
    • 免疫疾病
    • 传染病
    • 其他
  • 市场分析、洞察与预测：依最终用户划分
    • 医院和诊所
    • 诊断实验室
    • 研究机构和学术机构
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第6章 北美奈米医学市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲奈米医学市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 其他欧洲国家

第8章 亚太地区奈米医学市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 东南亚
    • 亚太其他地区

第9章 拉丁美洲奈米医学市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第10章 中东与非洲奈米医学市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • GCC国家
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 全球市场占有率分析（2023）
  • 公司简介
    • Gilead Sciences, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Jazz Pharmaceuticals plc
    • Nanospectra Biosciences, Inc.
    • Janssen Pharmaceuticals, Inc.
    • Merck &Co., Inc.
    • Amgen Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • Ipsen Pharma
Product Code: FBI110983

Growth Factors of nanomedicine Market

The global nanomedicine market size was valued at USD 263.68 billion in 2025. The market is projected to grow from USD 289.02 billion in 2026 to USD 759.09 billion by 2034, exhibiting a CAGR of 12.83% during the forecast period (2026-2034).

North America dominated the global nanomedicine market with a 46.12% market share in 2025, supported by advanced healthcare infrastructure, strong R&D capabilities, and a high prevalence of chronic diseases.

Nanomedicine involves the application of nanotechnology in medical diagnosis, drug delivery, and therapeutic interventions by utilizing nanoscale materials ranging between 1-100 nanometers. These technologies enable targeted delivery, enhanced bioavailability, and reduced systemic toxicity, making them highly effective for treating complex and chronic diseases. The expanding use of nanoparticles in pharmaceuticals, diagnostics, biomedical implants, tissue engineering, and regenerative medicine is accelerating global market growth.

MARKET OVERVIEW

The global nanomedicine market is witnessing strong growth due to increasing demand for precision medicine and advanced therapeutic solutions. Nanotechnology-based platforms are increasingly used to enhance drug solubility, stability, and controlled release, enabling improved patient outcomes. Growing investments in nanotechnology research, increasing clinical trials, and rising approvals of nano-based drugs and devices are further strengthening the market landscape.

The growing burden of chronic diseases such as cancer, cardiovascular disorders, neurodegenerative diseases, and diabetes has created substantial demand for targeted and minimally invasive treatment approaches, positioning nanomedicine as a critical component of modern healthcare.

MARKET DYNAMICS

Market Drivers

Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases globally is a major factor driving the growth of the nanomedicine market. Conditions such as cancer, diabetes, cardiovascular disorders, neurodegenerative diseases, and immune-related illnesses require long-term and targeted treatment approaches.

Traditional therapies often suffer from limitations such as poor drug efficacy, off-target toxicity, and limited bioavailability. Nanomedicine addresses these challenges by enabling controlled and site-specific drug delivery, improving therapeutic effectiveness while minimizing adverse effects.

For instance, in the United States, lung cancer cases increased from 221,097 in 2019 to 238,000 in 2023, according to the American Lung Association. This rising disease burden has increased demand for nano-based diagnostics and targeted cancer therapies, supporting market growth.

Increasing Demand for Targeted Drug Delivery Systems

The demand for targeted drug delivery systems is increasing due to rising concerns about side effects associated with conventional drug delivery. Nanocarriers such as liposomes, lipid nanoparticles, polymer-drug conjugates, and inorganic nanoparticles enable drugs to be delivered directly to diseased cells, enhancing efficacy and reducing systemic toxicity.

Continuous research and development activities, along with product launches of advanced nano-based delivery systems by pharmaceutical and biotechnology companies, are significantly contributing to market expansion.

Market Restraints

High Cost and Regulatory Challenges

The development and commercialization of nanomedicines involve high costs due to the need for specialized equipment, advanced manufacturing processes, and skilled expertise. These high costs can limit the participation of small and mid-sized companies.

Additionally, stringent regulatory requirements and complex approval pathways, particularly for safety and toxicity evaluation, pose challenges for market growth. The lack of standardized global regulatory frameworks further complicates the approval process, leading to delays in product launches.

Market Opportunities

Integration of Nanorobots for Drug Delivery and Diagnostics

The integration of nanorobotics in healthcare presents significant growth opportunities. Nanorobots enable ultra-precise drug delivery and real-time diagnostics at the cellular and molecular levels. Increasing investments in nanorobotics-based healthcare solutions, especially in emerging markets, are expected to create lucrative opportunities for market players.

For instance, in November 2024, Theranautilus (India) secured USD 1.2 million in seed funding to develop nanorobotics-based medical devices, highlighting growing investor interest in this segment.

Market Challenges

Lack of Standardized Regulatory Frameworks

One of the key challenges in the nanomedicine market is the absence of standardized regulatory guidelines across regions. This creates uncertainty in manufacturing, quality control, and commercialization. Additionally, the high cost of clinical trials and long development timelines pose barriers, particularly for smaller companies. Collaborative efforts between regulators, researchers, and industry stakeholders are required to streamline approvals while ensuring patient safety.

LATEST TRENDS

Rising Shift Toward Personalized Medicine

Personalized and precision medicine is emerging as a prominent trend in the global nanomedicine market. Nanotechnology enables the customization of therapies based on genetic, molecular, and phenotypic patient profiles, improving treatment outcomes and reducing adverse effects.

Biopharmaceutical companies are increasingly developing nano-enabled antibody-drug conjugates (ADCs), biomarker-targeted nanoparticles, and personalized drug delivery platforms. These advancements are expected to drive market growth throughout the forecast period.

SEGMENTATION ANALYSIS

By Type

Based on type, the market is segmented into therapeutics, diagnostics, and medical devices.

The therapeutics segment dominated the market with a 55.95% share in 2026, driven by increasing adoption of nano-based drug delivery systems for chronic and genetic diseases.

The diagnostics segment held the second-largest share due to rising demand for early and accurate disease diagnosis.

The medical devices segment is expected to grow substantially, supported by advancements in regenerative medicine and nano-coated implants.

By Molecule Type

The market is segmented into nanoparticles, nanoshells, nanotubes, and nanodevices.

The nanoparticles segment held the largest share of 76.20% in 2026, driven by extensive use in drug delivery and diagnostics. Lipid-based and polymer-based nanoparticles are widely adopted due to their biocompatibility and stability. Nanoshells are expected to register strong growth due to rising applications in targeted cancer therapy.

By Application

The market is categorized into oncology, neurodegenerative diseases, cardiovascular diseases, immunology, infectious diseases, and others.

The oncology segment dominated the market with a 43.52% share in 2026, supported by increasing cancer prevalence and continuous product launches. Neurodegenerative diseases are expected to grow at a significant CAGR due to advancements in nano-based brain-targeted therapies.

By End-user

Based on end-user, the market is segmented into hospitals and clinics, diagnostic laboratories, research and academic institutes, and others.

Hospitals and clinics dominated the market with a 49.86% share in 2026, driven by high patient inflow and increasing adoption of targeted therapies. Research and academic institutes are expected to register the highest growth rate due to rising focus on nanomedicine research and development.

REGIONAL OUTLOOK

North America generated USD 121.61 billion in revenue in 2025, driven by high FDA approvals and strong R&D investments.

Asia Pacific is expected to grow at the highest CAGR, supported by increasing clinical trials, government funding, and expanding healthcare infrastructure in China, Japan, and India.

Europe accounted for a substantial share due to advanced healthcare systems and strong research collaborations.

Latin America and the Middle East & Africa are expected to grow steadily, supported by improving research networks and healthcare investments.

COMPETITIVE LANDSCAPE

Key Market Players

Major companies operating in the global nanomedicine market include:

  • Pfizer Inc.
  • Janssen Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Gilead Sciences, Inc.
  • Jazz Pharmaceuticals plc
  • Nanospectra Biosciences, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Ipsen Pharma

These players focus on strategic collaborations, acquisitions, R&D investments, and product launches to strengthen their market positions.

KEY INDUSTRY DEVELOPMENTS

  • September 2023 - Evonik expanded its nanoparticle technology portfolio for parenteral drug delivery
  • June 2023 - BIONANOSIM partnered with RAFARM to establish BNS Ophthalmics
  • March 2023 - Moderna collaborated with Generation Bio for non-viral genetic medicines
  • January 2022 - Pfizer entered a development agreement with Acuitas Therapeutics for lipid nanoparticle delivery systems

CONCLUSION

The global nanomedicine market is demonstrating strong and sustained growth, supported by rapid advancements in nanotechnology, increasing adoption of targeted drug delivery systems, and rising demand for precision and personalized medicine. With the market valued at USD 263.68 billion in 2025 and expected to reach USD 759.09 billion by 2034, nanomedicine is emerging as a critical pillar of next-generation healthcare solutions.

The expanding burden of chronic diseases such as cancer, cardiovascular disorders, neurodegenerative conditions, and infectious diseases continues to drive demand for nano-enabled diagnostics and therapeutics. The dominance of the therapeutics segment and nanoparticles molecule type highlights the growing reliance on nano-based platforms for improving drug efficacy, safety, and patient outcomes. Additionally, the oncology application segment remains a key revenue contributor due to continuous innovation and product launches in targeted cancer therapies.

Regionally, North America maintains its leadership position due to strong regulatory support, high R&D investments, and a large number of approved nanomedicines, while Asia Pacific is expected to witness the fastest growth owing to increasing clinical trials, government funding, and expanding healthcare infrastructure. Europe continues to benefit from robust research collaborations and advanced healthcare systems.

Despite challenges related to high development costs and regulatory complexities, ongoing technological innovations, increasing investments, and growing focus on nanorobotics and personalized medicine are expected to strengthen the market outlook. Strategic initiatives by key players, including partnerships, acquisitions, and new product developments, are likely to further accelerate the adoption of nanomedicine across multiple therapeutic areas during the forecast period.

Segmentation By Type

  • Therapeutics
    • Biologics
    • Small Molecules
  • Diagnostics
    • IVD
    • Imaging
    • Others
  • Medical Devices
    • Regenerative Medicine
    • Implants

By Molecule Type

  • Nanoparticles
    • Lipid-Based
    • Polymers & Polymer Drug Conjugates
    • Inorganic Nanoparticles
    • Others
  • Nanoshells
  • Nanotubes
  • Nanodevices

By Application

  • Oncology
  • Neurodegenerative Diseases
  • Cardiovascular Diseases
  • Immunology
  • Infectious Diseases
  • Others

By End-user

  • Hospitals and Clinics
  • Diagnostics Laboratories
  • Research and Academic Institutes
  • Others

By Geography

  • North America (By Type, By Molecule Type, By Application, By End-user, and By Country)
    • U.S.
    • Canada
  • Europe ( By Type, By Molecule Type, By Application, By End-user, and By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Type, By Molecule Type, By Application, By End-user, and By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America ( By Type, By Molecule Type, By Application, By End-user, and By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa ( By Type, By Molecule Type, By Application, By End-user, and By Country/Sub-Region)
    • GCC
    • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Disease, By Key Countries/ Regions, 2025
  • 4.2. Overview: Application of Nanomedicine in Healthcare
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches etc.)
  • 4.4. Pipeline Analysis
  • 4.5. Impact of COVID-19 on the Global Nanomedicine Market

5. Global Nanomedicine Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Therapeutics
      • 5.1.1.1. Biologics
      • 5.1.1.2. Small Molecules
    • 5.1.2. Diagnostics
      • 5.1.2.1. IVD
      • 5.1.2.2. Imaging
      • 5.1.2.3. Others
    • 5.1.3. Medical Devices
      • 5.1.3.1. Regenerative Medicine
      • 5.1.3.2. Implants
  • 5.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 5.2.1. Nanoparticles
      • 5.2.1.1. Lipid Based
      • 5.2.1.2. Polymers & Polymer Drug Conjugates
      • 5.2.1.3. Inorganic Nanoparticles
      • 5.2.1.4. Others
    • 5.2.2. Nanoshells
    • 5.2.3. Nanotubes
    • 5.2.4. Nanodevices
  • 5.3. Market Analysis, Insights and Forecast - By Application
    • 5.3.1. Oncology
    • 5.3.2. Neurodegenerative Diseases
    • 5.3.3. Cardiovascular Diseases
    • 5.3.4. Immunology
    • 5.3.5. Infectious Diseases
    • 5.3.6. Others
  • 5.4. Market Analysis, Insights and Forecast - By End-user
    • 5.4.1. Hospitals and Clinics
    • 5.4.2. Diagnostics Laboratories
    • 5.4.3. Research and Academic Institutes
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Nanomedicine Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Therapeutics
      • 6.1.1.1. Biologics
      • 6.1.1.2. Small Molecules
    • 6.1.2. Diagnostics
      • 6.1.2.1. IVD
      • 6.1.2.2. Imaging
      • 6.1.2.3. Others
    • 6.1.3. Medical Devices
      • 6.1.3.1. Regenerative Medicine
      • 6.1.3.2. Implants
  • 6.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 6.2.1. Nanoparticles
      • 6.2.1.1. Lipid Based
      • 6.2.1.2. Polymers & Polymer Drug Conjugates
      • 6.2.1.3. Inorganic Nanoparticles
      • 6.2.1.4. Others
    • 6.2.2. Nanoshells
    • 6.2.3. Nanotubes
    • 6.2.4. Nanodevices
  • 6.3. Market Analysis, Insights and Forecast - By Application
    • 6.3.1. Oncology
    • 6.3.2. Neurodegenerative Diseases
    • 6.3.3. Cardiovascular Diseases
    • 6.3.4. Immunology
    • 6.3.5. Infectious Diseases
    • 6.3.6. Others
  • 6.4. Market Analysis, Insights and Forecast - By End-user
    • 6.4.1. Hospitals and Clinics
    • 6.4.2. Diagnostics Laboratories
    • 6.4.3. Research and Academic Institutes
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Nanomedicine Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Therapeutics
      • 7.1.1.1. Biologics
      • 7.1.1.2. Small Molecules
    • 7.1.2. Diagnostics
      • 7.1.2.1. IVD
      • 7.1.2.2. Imaging
      • 7.1.2.3. Others
    • 7.1.3. Medical Devices
      • 7.1.3.1. Regenerative Medicine
      • 7.1.3.2. Implants
  • 7.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 7.2.1. Nanoparticles
      • 7.2.1.1. Lipid Based
      • 7.2.1.2. Polymers & Polymer Drug Conjugates
      • 7.2.1.3. Inorganic Nanoparticles
      • 7.2.1.4. Others
    • 7.2.2. Nanoshells
    • 7.2.3. Nanotubes
    • 7.2.4. Nanodevices
  • 7.3. Market Analysis, Insights and Forecast - By Application
    • 7.3.1. Oncology
    • 7.3.2. Neurodegenerative Diseases
    • 7.3.3. Cardiovascular Diseases
    • 7.3.4. Immunology
    • 7.3.5. Infectious Diseases
    • 7.3.6. Others
  • 7.4. Market Analysis, Insights and Forecast - By End-user
    • 7.4.1. Hospitals and Clinics
    • 7.4.2. Diagnostics Laboratories
    • 7.4.3. Research and Academic Institutes
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Nanomedicine Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Therapeutics
      • 8.1.1.1. Biologics
      • 8.1.1.2. Small Molecules
    • 8.1.2. Diagnostics
      • 8.1.2.1. IVD
      • 8.1.2.2. Imaging
      • 8.1.2.3. Others
    • 8.1.3. Medical Devices
      • 8.1.3.1. Regenerative Medicine
      • 8.1.3.2. Implants
  • 8.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 8.2.1. Nanoparticles
      • 8.2.1.1. Lipid Based
      • 8.2.1.2. Polymers & Polymer Drug Conjugates
      • 8.2.1.3. Inorganic Nanoparticles
      • 8.2.1.4. Others
    • 8.2.2. Nanoshells
    • 8.2.3. Nanotubes
    • 8.2.4. Nanodevices
  • 8.3. Market Analysis, Insights and Forecast - By Application
    • 8.3.1. Oncology
    • 8.3.2. Neurodegenerative Diseases
    • 8.3.3. Cardiovascular Diseases
    • 8.3.4. Immunology
    • 8.3.5. Infectious Diseases
    • 8.3.6. Others
  • 8.4. Market Analysis, Insights and Forecast - By End-user
    • 8.4.1. Hospitals and Clinics
    • 8.4.2. Diagnostics Laboratories
    • 8.4.3. Research and Academic Institutes
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Nanomedicine Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Therapeutics
      • 9.1.1.1. Biologics
      • 9.1.1.2. Small Molecules
    • 9.1.2. Diagnostics
      • 9.1.2.1. IVD
      • 9.1.2.2. Imaging
      • 9.1.2.3. Others
    • 9.1.3. Medical Devices
      • 9.1.3.1. Regenerative Medicine
      • 9.1.3.2. Implants
  • 9.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 9.2.1. Nanoparticles
      • 9.2.1.1. Lipid Based
      • 9.2.1.2. Polymers & Polymer Drug Conjugates
      • 9.2.1.3. Inorganic Nanoparticles
      • 9.2.1.4. Others
    • 9.2.2. Nanoshells
    • 9.2.3. Nanotubes
    • 9.2.4. Nanodevices
  • 9.3. Market Analysis, Insights and Forecast - By Application
    • 9.3.1. Oncology
    • 9.3.2. Neurodegenerative Diseases
    • 9.3.3. Cardiovascular Diseases
    • 9.3.4. Immunology
    • 9.3.5. Infectious Diseases
    • 9.3.6. Others
  • 9.4. Market Analysis, Insights and Forecast - By End-user
    • 9.4.1. Hospitals and Clinics
    • 9.4.2. Diagnostics Laboratories
    • 9.4.3. Research and Academic Institutes
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Nanomedicine Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Therapeutics
      • 10.1.1.1. Biologics
      • 10.1.1.2. Small Molecules
    • 10.1.2. Diagnostics
      • 10.1.2.1. IVD
      • 10.1.2.2. Imaging
      • 10.1.2.3. Others
    • 10.1.3. Medical Devices
      • 10.1.3.1. Regenerative Medicine
      • 10.1.3.2. Implants
  • 10.2. Market Analysis, Insights and Forecast - By Molecule Type
    • 10.2.1. Nanoparticles
      • 10.2.1.1. Lipid Based
      • 10.2.1.2. Polymers & Polymer Drug Conjugates
      • 10.2.1.3. Inorganic Nanoparticles
      • 10.2.1.4. Others
    • 10.2.2. Nanoshells
    • 10.2.3. Nanotubes
    • 10.2.4. Nanodevices
  • 10.3. Market Analysis, Insights and Forecast - By Application
    • 10.3.1. Oncology
    • 10.3.2. Neurodegenerative Diseases
    • 10.3.3. Cardiovascular Diseases
    • 10.3.4. Immunology
    • 10.3.5. Infectious Diseases
    • 10.3.6. Others
  • 10.4. Market Analysis, Insights and Forecast - By End-user
    • 10.4.1. Hospitals and Clinics
    • 10.4.2. Diagnostics Laboratories
    • 10.4.3. Research and Academic Institutes
    • 10.4.4. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2023)
  • 11.2. Company Profiles
    • 11.2.1. Gilead Sciences, Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Teva Pharmaceutical Industries Ltd.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Pfizer Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Jazz Pharmaceuticals plc
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Nanospectra Biosciences, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Janssen Pharmaceuticals, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Merck & Co., Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Amgen Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Arrowhead Pharmaceuticals, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Ipsen Pharma
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Nanomedicine Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Nanomedicine Market Revenue (USD billion) Forecast, by Therapeutics, 2021-2034
  • Table 3: Global Nanomedicine Market Revenue (USD billion) Forecast, by Diagnostics, 2021-2034
  • Table 4: Global Nanomedicine Market Revenue (USD billion) Forecast, by Medical Devices, 2021-2034
  • Table 5: Global Nanomedicine Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 6: Global Nanomedicine Market Revenue (USD billion) Forecast, by Nanoparticles, 2021-2034
  • Table 7: Global Nanomedicine Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 8: Global Nanomedicine Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 9: Global Nanomedicine Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 10: North America Nanomedicine Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 11: North America Nanomedicine Market Revenue (USD billion) Forecast, by Therapeutics, 2021-2034
  • Table 12: North America Nanomedicine Market Revenue (USD billion) Forecast, by Diagnostics, 2021-2034
  • Table 13: North America Nanomedicine Market Revenue (USD billion) Forecast, by Medical Devices, 2021-2034
  • Table 14: North America Nanomedicine Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 15: North America Nanomedicine Market Revenue (USD billion) Forecast, by Nanoparticles, 2021-2034
  • Table 16: North America Nanomedicine Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 17: North America Nanomedicine Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 18: North America Nanomedicine Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 19: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 20: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Therapeutics, 2021-2034
  • Table 21: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Diagnostics, 2021-2034
  • Table 22: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Medical Devices, 2021-2034
  • Table 23: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 24: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Nanoparticles, 2021-2034
  • Table 25: Europe Nanomedicine Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 26: Europe Nanomedicine Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 27: Europe Nanomedicine Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 28: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 29: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Therapeutics, 2021-2034
  • Table 30: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Diagnostics, 2021-2034
  • Table 31: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Medical Devices, 2021-2034
  • Table 32: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 33: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Nanoparticles, 2021-2034
  • Table 34: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 35: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 36: Asia Pacific Nanomedicine Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 37: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 38: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Therapeutics, 2021-2034
  • Table 39: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Diagnostics, 2021-2034
  • Table 40: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Medical Devices, 2021-2034
  • Table 41: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 42: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Nanoparticles, 2021-2034
  • Table 43: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 44: Latin America Nanomedicine Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 45: Latin America Nanomedicine Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 46: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 47: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Therapeutics, 2021-2034
  • Table 48: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Diagnostics, 2021-2034
  • Table 49: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Medical Devices, 2021-2034
  • Table 50: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Molecule Type, 2021-2034
  • Table 51: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Nanoparticles, 2021-2034
  • Table 52: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 53: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 54: Middle East & Africa Nanomedicine Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Nanomedicine Market Revenue Breakdown (USD billion, %) by Region, 2023 & 2034
  • Figure 2: Global Nanomedicine Market Value Share (%), by Type, 2023 & 2034
  • Figure 3: Global Nanomedicine Market Value Share (%), by Molecule Type, 2023 & 2034
  • Figure 4: Global Nanomedicine Market Value Share (%), by Application, 2023 & 2034
  • Figure 5: Global Nanomedicine Market Value Share (%), by End-user, 2023 & 2034
  • Figure 6: Global Nanomedicine Market Value (USD billion), by Region, 2023 & 2034
  • Figure 7: North America Nanomedicine Market Value (USD billion), by Type, 2023 & 2034
  • Figure 8: North America Nanomedicine Market Value Share (%), by Type, 2023
  • Figure 9: North America Nanomedicine Market Value (USD billion), by Molecule Type, 2023 & 2034
  • Figure 10: North America Nanomedicine Market Value Share (%), by Molecule Type, 2023
  • Figure 11: North America Nanomedicine Market Value (USD billion), by Application, 2023 & 2034
  • Figure 12: North America Nanomedicine Market Value Share (%), by Application, 2023
  • Figure 13: North America Nanomedicine Market Value (USD billion), by End-user, 2023 & 2034
  • Figure 14: North America Nanomedicine Market Value Share (%), by End-user, 2023
  • Figure 15: North America Nanomedicine Market Value (USD billion), By Country, 2023 & 2034
  • Figure 16: North America Nanomedicine Market Value Share (%), By Country, 2023
  • Figure 17: Europe Nanomedicine Market Value (USD billion), by Type, 2023 & 2034
  • Figure 18: Europe Nanomedicine Market Value Share (%), by Type, 2023
  • Figure 19: Europe Nanomedicine Market Value (USD billion), by Molecule Type, 2023 & 2034
  • Figure 20: Europe Nanomedicine Market Value Share (%), by Molecule Type, 2023
  • Figure 21: Europe Nanomedicine Market Value (USD billion), by Application, 2023 & 2034
  • Figure 22: Europe Nanomedicine Market Value Share (%), by Application, 2023
  • Figure 23: Europe Nanomedicine Market Value (USD billion), by End-user, 2023 & 2034
  • Figure 24: Europe Nanomedicine Market Value Share (%), by End-user, 2023
  • Figure 25: Europe Nanomedicine Market Value (USD billion), By Country/ Sub-region, 2023 & 2034
  • Figure 26: Europe Nanomedicine Market Value Share (%), By Country/ Sub-region, 2023
  • Figure 27: Asia Pacific Nanomedicine Market Value (USD billion), by Type, 2023 & 2034
  • Figure 28: Asia Pacific Nanomedicine Market Value Share (%), by Type, 2023
  • Figure 29: Asia Pacific Nanomedicine Market Value (USD billion), by Molecule Type, 2023 & 2034
  • Figure 30: Asia Pacific Nanomedicine Market Value Share (%), by Molecule Type, 2023
  • Figure 31: Asia Pacific Nanomedicine Market Value (USD billion),by Application, 2023 & 2034
  • Figure 32: Asia Pacific Nanomedicine Market Value Share (%), by Application, 2023
  • Figure 33: Asia Pacific Nanomedicine Market Value (USD billion), by End-user, 2023 & 2034
  • Figure 34: Asia Pacific Nanomedicine Market Value Share (%), by End-user, 2023
  • Figure 35: Asia Pacific Nanomedicine Market Value (USD billion), By Country/ Sub-region, 2023 & 2034
  • Figure 36: Asia Pacific Nanomedicine Market Value Share (%), By Country/ Sub-region, 2023
  • Figure 37: Latin America Nanomedicine Market Value (USD billion), by Type, 2023 & 2034
  • Figure 38: Latin America Nanomedicine Market Value Share (%), by Type, 2023
  • Figure 39: Latin America Nanomedicine Market Value (USD billion), by Molecule Type, 2023 & 2034
  • Figure 40: Latin America Nanomedicine Market Value Share (%), by Molecule Type, 2023
  • Figure 41: Latin America Nanomedicine Market Value (USD billion), by Application, 2023 & 2034
  • Figure 42: Latin America Nanomedicine Market Value Share (%), by Application, 2023
  • Figure 43: Latin America Nanomedicine Market Value (USD billion), by End-user, 2023 & 2034
  • Figure 44: Latin America Nanomedicine Market Value Share (%), by End-user, 2023
  • Figure 45: Latin America Nanomedicine Market Value (USD billion), By Country/ Sub-region, 2023 & 2034
  • Figure 46: Latin America Nanomedicine Market Value Share (%), By Country/ Sub-region, 2023
  • Figure 47: Middle East & Africa Nanomedicine Market Value (USD billion), by Type, 2023 & 2034
  • Figure 48: Middle East & Africa Nanomedicine Market Value Share (%), by Type, 2023
  • Figure 49: Middle East & Africa Nanomedicine Market Value (USD billion), by Molecule Type, 2023 & 2034
  • Figure 50: Middle East & Africa Nanomedicine Market Value Share (%), by Molecule Type, 2023
  • Figure 51: Middle East & Africa Nanomedicine Market Value (USD billion), by Application, 2023 & 2034
  • Figure 52: Middle East & Africa Nanomedicine Market Value Share (%), by Application, 2023
  • Figure 53: Middle East & Africa Nanomedicine Market Value (USD billion), by End-user, 2023 & 2034
  • Figure 54: Middle East & Africa Nanomedicine Market Value Share (%), by End-user, 2023
  • Figure 55: Middle East & Africa Nanomedicine Market Value (USD billion), By Country/ Sub-region, 2023 & 2034
  • Figure 56: Middle East & Africa Nanomedicine Market Value Share (%), By Country/ Sub-region, 2023
  • Figure 57: Global Nanomedicine Market Share (%), By Company, 2023